Oppenheimer Cuts Viracta Therapeutics (NASDAQ:VIRX) Price Target to $11.00

Viracta Therapeutics (NASDAQ:VIRX) had its target price lowered by Oppenheimer from $13.00 to $11.00 in a report released on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Viracta Therapeutics in a report on Tuesday, April 16th.

Viracta Therapeutics Stock Performance

Shares of NASDAQ:VIRX opened at $0.76 on Thursday. The firm has a market cap of $29.88 million, a PE ratio of -0.62 and a beta of 0.95. The firm’s fifty day moving average is $0.93 and its 200-day moving average is $0.72. Viracta Therapeutics has a 52 week low of $0.43 and a 52 week high of $2.13.

Viracta Therapeutics (NASDAQ:VIRX) last released its earnings results on Thursday, March 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.05). Sell-side analysts forecast that Viracta Therapeutics will post -1.06 EPS for the current year.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.